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tion. Failure to acknowledge that more than one entity may be present precludes attempts to
understand interactive relationships. The clinicopathological studies of dementia demonstrate that
multiple pathologic processes often coexist.
How overlapping pathologic findings affect the diagnosis and treatment of clinical AD and other
dementia phenotypes was the topic taken up by the Alzheimer’s Association’s Research Roundtable
in October 2014. This review will cover the neuropathologic basis of dementia, provide clinical per-
spectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pa-
thologies and how these issues impact clinical trials.High prevalence of multiple pathologic findings
among individuals with clinical diagnosis of AD suggests that new treatment strategies may be
needed to effectively treat AD and other dementing illnesses.
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Converging research has shown the complexity ofmultiple
pathologic substrates underlying clinical Alzheimer’s disease
(AD), with closely related and perhaps synergistic pathologicimer’s Association. This is an open access article under the CC BY-NC-ND
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pathologies (i.e., cerebrovascular disease, Lewy bodies [LBs],
hippocampal sclerosis [HS] with or without TAR DNA-
binding protein 43 [TDP-43] inclusions, non-AD tauopathies,
neuroinflammation, etc.) could influence clinical trial strate-
gies and outcomes and lead to novel therapeutic approaches.2. Methods
How overlapping pathologic findings affect the diagnosis
and treatment of clinical AD and other dementia phenotypes
was the topic taken up by the Alzheimer’s Association’s
Research Roundtable in October 2014. The meeting pro-
vided a forum for experts from academia, industry, funding
and regulatory agencies, and payer groups to consider the
implications of overlapping pathologic findings on the dis-
covery of new drug targets, therapeutic approaches, trial de-
signs, and the regulatory approval of new drugs. The
objective of this article is to provide a summary of the topics
discussed at the Research Roundtable meeting and provide a
review of the latest understanding of these issues and their
implications for drug development in AD.AD; 43.7%
AD+VaD; 
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AD+LBD; 
16.7%
AD+tau; 1.7%
AD+HS; 0.5%
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Fig. 1. Multiple pathologic findings when AD is present. A total of 1242
brains were included: all Braak stage IV or greater and Thal phase 3 or
greater. Eighty-six percent of patients had a primary clinical diagnosis of de-
mentia and 14% were diagnosed with parkinsonism. “Tau” indicates argyr-
ophilic grain disease, an age-associated medial temporal tauopathy.
Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia; LBD,
Lewy body disease; HS, hippocampal sclerosis.3. Discussion
3.1. The neuropathologic basis of dementia
Although neuropathologic diagnosis is considered the
gold standard for determining the etiologic cause of a
dementia syndrome, this approach has limitations. Neuro-
pathologic examination is the only technique that enables
visualization of abnormal structures at a microscopic
level—plaques, tangles, LBs, neuronal loss, infarcts, etc.—
yet it provides only a snapshot of the brain at one point in
time. Neuropathology provides limited information
regarding the age of lesions, their relationship to one another
over time, or their relationship to the real-time clinical char-
acteristics of the disease. Longitudinal cohort studies with
annual testing have improved clinical correlation with
pathology. Indeed, observational studies such as the longitu-
dinal Nun Study, which began in 1986 with annual examina-
tions and by 1997 included autopsies on 146 participants,
found pathologic indicators of AD even in the brains
of cognitively normal individuals evaluated clinically prox-
imate to death [1]. These studies, along with amyloid
positron emission tomography (PET) imaging and cerebro-
spinal fluid (CSF) biomarkers, support the concept of pre-
clinical disease which is now codified into the revised
National Institute on Aging and Alzheimer’s Association
(NIA-AA) diagnostic guidelines [2–4].
After the publication of the revised diagnostic criteria, it
became clear that the criteria for postmortem pathologic
diagnosis of AD also required updating to reflect knowledge
that has accumulated since the last consensus criteria were
published in 1997 [5]. These new criteria, also proposed
by an NIA-AA working group [6], aim to disentangle theclinicopathologic term “Alzheimer’s disease” from the
neuropathologic changes seen in the AD brain, including
brain lesions that reflect comorbid conditions that are com-
mon among the elderly.
These new criteria recommended classifying “AD
neuropathologic change (ADNC)” according to three
different staging schemes: the distribution of amyloid b
(Ab) deposits with Thal stages [7], neurofibrillary pathol-
ogy with Braak stages [8,9], and the presence and
severity of neuritic plaques according to the Consortium
to Establish a Registry for Alzheimer’s Disease [10].
Combining results from these three variables yields an
estimate of no, low, medium, or high ADNCs. Those with
intermediate or high ADNC are considered to have suffi-
cient pathology to confirm a clinical diagnosis of AD
dementia during life. The working group also made recom-
mendations regarding how to report findings for common
comorbidities, including Lewy body disease (LBD),
vascular brain injury (VBI), and HS, and other neuropath-
ologic findings such as TDP-43 inclusions and argyrophilic
grain disease (AGD). LBD, VBI, HS, and TDP-43 inclu-
sions have all been shown to independently contribute to
cognitive impairment [11–14], whereas the clinical
significance of AGD is less well established [15].
The new NIA-AA neuropathologic criteria for AD reflect
recent studies suggesting that a minority of persons with
clinical diagnosis of AD have “pure AD,” that is, only plaque
and tangle pathology. For example, in the State of Florida
Department of Elder Affairs Alzheimer’s Disease Initiative
(ADI) Brain Bank at Mayo Clinic in Jacksonville, which
in 2014 included 1242 brains collected from memory disor-
ders clinics across the state, fewer than half of all patients
with a primary pathologic diagnosis of AD had “pure AD”
neuropathology (Fig. 1) (unpublished data).
Another analysis by the Religious Orders Study (ROS)
and the Rush Memory and Aging Project found that 45.8%
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those with mild cognitive impairment (MCI) had multiple
pathologies [16]. Other studies have shown that between
30% and 57% of brains with AD pathologic diagnosis
have TDP-43 pathology in the medial temporal lobe
[17,18] and that cases with TDP-43 pathology have greater
regional brain atrophy and more severe cognitive impair-
ment [18–20]. The most significant predictor of TDP-43
pathology in AD is HS [21]. In the Florida ADI Brain
Bank, HS was detected in 20% of patients with dementia
[22]. In a separate study, almost half of AD cases were
shown to have LBs. LB copathology in AD is further classi-
fied based on the anatomic distribution of LBs: brainstem,
limbic, or diffuse cortical. In some cases, LB copathology
in AD is confined to the amygdala. Such cases are sometimes
classified as the LB variant of AD [23].
The Rush study also examined the influence of overlap-
ping pathologic processes on cognitive impairment. The
majority of patients with an antemortem clinical diagnosis
of AD dementia were found to have multiple pathologies
at autopsy, with about half having, in addition to AD, one
or more of the following: LBs, TDP-43, HS, and vascular
diseases. Each pathology appears to have separate but addi-
tive effects on cognition. How these different pathologic
processes interact remains unclear, although some experi-
mental data suggest that Ab deposition may affect tau
[24,25] and a-synuclein accumulation [26].
Moreover, the distribution of neurofibrillary tangles in
patients with AD does not always conform to typical Braak
staging. A study that queried the brain bank database at the
Mayo Clinic in Jacksonville, FL, found that of 889 AD cases
studied, about a quarter fell into two “atypical” patterns:
11% had hippocampal sparing (HpSp) and 14% had
limbic-predominant (LP) tangle pathology [27]. Interest-
ingly, the HpSp subgroup experienced more rapid decline,
whereas the LP subgroup showed a slower rate of decline.
Those in the HpSp subgroup also tended to be younger,
more often present with nonamnestic clinical syndromes,
and showed shorter disease duration and less concurrent
pathology.
Vascular lesions are also frequently comorbid with AD
and contribute to cognitive decline. In the ADI analysis,
44% of AD cases also had vascular pathology, including
28% with small-vessel disease (lacunar infarcts, microin-
farcts, or cribriform change), 12% with severe leukoence-
phalopathy, 10% with severe amyloid angiopathy, 2%
with large-vessel infarcts, and ,1% with large hematomas
(personal communication, presented at Research Roundta-
ble by Dennis Dickson). The ROS/Rush study measured
different frequencies: among patients with probable AD,
approximately one-third had gross infarcts, one-fourth
had microinfarcts, and about one-third had moderate-to-
severe cerebral amyloid angiopathy (CAA) [28]. In
addition, one-third of probable AD patients had
moderate-to-severe atherosclerosis and moderate-to-
severe arteriolosclerosis.3.2. Clinical perspectives on multiple pathologies
The prevalence of most neuropathologic findings in-
creases with age. Therefore, the high rate of multiple pathol-
ogies found in neuropathologic studies, such as those
described previously, may be related to the high mean age
of death (meanw90 years) of participants in most autopsy
studies [14]. At the other end of the spectrum, clinical
research typically involves younger patients with fewer
comorbid pathologic findings, meaning that the problem is
less of an issue in younger dementia patient cohorts.
Researchers should consider copathologies in clinical trials,
although the prevalence and impact may be lower in a
younger population than the autopsy studies, composed of
older populations, may suggest.
According to data collected by the National Alzheimer’s
Coordinating Center using the 1997NIA-Reagan neuropatho-
logic criteria as the gold standard [5], the sensitivity of clinical
diagnosis of AD ranged from 70.9% to 87.3% and the speci-
ficity ranged from44.3% to70.8% [29]. Among those subjects
whoweremisdiagnosed, the primaryneuropathologic findings
were tauopathies such asAGD, aswell as frontotemporal lobar
degeneration (FTLD), cerebrovascular disease, LBD, and HS.
FTLD comprises a family of disorders, differentiated
clinically by behavioral, language (semantic or agrammatic),
or parkinsonian variants (progressive supranuclear palsy and
corticobasal degeneration). The neuropathologic diagnosis
of FTLD is further broken down by the presence of tau,
TDP-43, or the RNA-binding protein fused in sarcoma
(FUS) pathology [30]. The links between clinical phenotype
and pathology vary for each syndrome, and both the clinical
and pathologic features overlap with AD. When evidence of
both frontotemporal dementia (FTD) and AD pathologic
processes coexists in a patient, both may contribute to the
clinical phenotype [31].
LBD symptoms can be differentiated by fluctuating
cognition, visual hallucinations, Parkinsonism, and rapid
eye movement sleep behavior disorder. While most non-
AD pathologic processes increase with age, LB frequency
either plateaus or declines in older cohorts, further compli-
cating diagnosis when multiple pathologies are present.
Neuropathology studies have found divergent results
regarding the clinical effects of concomitant LB pathology
in AD. Some studies report that the combination of AD
and LB pathology affects the cognitive presentation of
dementia [32,33] but not the rate of cognitive decline [33].
However, one recent study failed to find clinical or neuropsy-
chological predictors that could differentiate between AD
with or without concomitant LB [34].
In AD, TDP-43 pathology is found in about 20% to 50%
of AD brains, particularly in the amygdala and medial tem-
poral lobe [18,35], and correlates with more rapid cognitive
decline, even after controlling for other pathologies,
particularly in the domains of episodic and working
memory (Fig. 2) [20]. Moreover, TDP-43 deposition appears
to progress in a stereotypic manner similar to tau, which
Fig. 2. Ten-year paths of global cognitive decline in 130 participants from
the Religious Order Study with varying levels of TDP-43 pathology,
adjusted for age at death, amyloid, tangles, and hippocampal sclerosis.
Black line, no TDP-43; green line, 10th percentile; blue line, 50th percen-
tile; and red line, 90th percentile TDP-43 [20].
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tion, memory loss, and medial temporal atrophy [36].
The presence of FTLD or LBD pathology can be pre-
dicted albeit with moderate sensitivity and specificity, on
clinical grounds. For cerebrovascular disease, the Hachinski
Ischemic Score has been widely used to identify vascular de-
mentia on clinical grounds but also with only moderate
sensitivity and specificity for separating pure AD from AD
with cerebrovascular copathology [37]. The addition of
magnetic resonance imaging (MRI) allows identification of
clinically unrecognized brain infarcts, microbleeds, and
white matter hyperintensities of presumed vascular origin.
However, MRI signs of cerebrovascular disease may not al-
ways be clinically relevant for cognition, and our under-
standing of the relationship between cerebral small-vessel
disease burden and risk for dementia is incomplete. Further-
more, commonly available MRI (1.5 or 3.0 T) cannot detect
microinfarcts, which are very common and are associated
with dementia risk [38]. Therefore, MRI is a useful adjunct
to increase the sensitivity for detection of cerebrovascular
disease but still does not capture the full spectrum of cere-
brovascular pathology. In the ROS, macroscopic infarcts,
microinfarcts, and CAA were independently and additively
associated with antemortem cognitive decline and/or risk
for dementia, including when AD pathology was addition-
ally present [39–41]. In clinical trials, comorbid
cerebrovascular pathology could affect trial results or even
obscure beneficial effects on AD if there are off-target
drug effects. For example, patients with CAA appear to be
at higher risk for amyloid-related imaging abnormalities in
AD immunotherapy trials [42].3.3. Therapeutics/targeting overlapping pathology
Emerging evidence suggests that AD and other neurode-
generative diseases may be driven by cell-to-cell transmis-
sion of pathologic proteins such as Ab, tau, a-synuclein,
and TDP-43 [43]. These proteins appear to become patho-
logic through conformational changes such as misfolding,
oligomerization, fibrillization, and aggregation. These
abnormal conformers then appear to serve as seeds or tem-
plates for assembly of additional protein aggregates that
can be transmitted neuron to neuron [44–46]. This process
could explain the spatiotemporal progression of pathology
in the brain. While the mechanisms of this process are
only beginning to be understood, it has nevertheless given
rise to novel therapeutic approaches. For example,
antibodies or small molecules may be generated that target
different protein structures, either stabilizing them so they
do not form fibrils or aggregates or by preventing their
transmission [47,48]. Clinical trials are already in progress
testing this strategy. For example, there is a phase 1 trial of
an antibody against a-synuclein in patients with
Parkinson’s disease (PD) (NCT02095171 and
NCT02157714), antitau antibodies have shown promising
results in animal models of tauopathies [49], and early hu-
man studies are just getting underway.
Elucidating the mechanisms whereby abnormal con-
formers of key pathogenic proteins induce neurodegenera-
tion could also reveal new treatment approaches. Toxicity
from the RNA-binding protein TDP-43, for example,
appears to result from both gain- and loss-of-function mech-
anisms, with posttranslational modifications conferring
toxic properties that disrupt normal transport of mRNA to
the synapse [50]. The mechanisms of TDP-43 misregulation
and propagation are unknown. New animal models and a
TDP-43–specific imaging agent could speed the identifica-
tion of therapeutic targets and the development of new drugs.
Targeting amyloid in the vasculature presents additional
complexity. In the ROS/Rush studies mentioned earlier,
CAA was present in about 80% of individuals at autopsy,
and the severity of CAA correlated with cognitive impair-
ment [51]. Candidate treatment approaches to prevent depo-
sition of Ab in the arteries include approaches that reduce
Ab production, increase its clearance, or block its toxicity.
Immunotherapy approaches to clear amyloid from the ves-
sels could have negative consequences, such as increasing
the risk of amyloid-related microbleeds as noted by imaging
abnormalities [42,52].
Vascular pathology caused by atherosclerosis, arterio-
sclerosis, or embolism is the only common comorbid pathol-
ogy of AD that is potentially treatable with current
pharmacotherapies and lifestyle modification. However,
although there is some evidence that blood pressure control
may prevent dementia, there is not yet strong evidence for
treatment of other vascular risk factors [53]. Investigators
planning future trials in AD may wish to take steps to ensure
that vascular risk factors are balanced between randomized
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to ensure similar treatment of blood pressure and other
vascular risk factors in all trial patients.
Treating the comorbid pathologic processes so common
in AD and related neurodegenerative diseases may ulti-
mately require combination therapy; however, evaluating
the effectiveness of combination approaches presents chal-
lenges in both drug discovery and clinical trials. For
example, there currently are no accepted animal models
that reflect therapeutic pathways for testing treatments or
understanding multiple pathologies. As a result, combinato-
rial approaches may have to be advanced to human studies
by demonstrating target engagement in humans.3.4. Biomarkers and imaging
Progress in understanding nonamyloid pathologic pro-
cesses and developing treatments for them requires
improved biomarkers and imaging tools. Recent advances
in developing radioligands for tau PET imaging, for
example, may enable the differential diagnosis of the various
tauopathies [54]. Although tau is molecularly heteroge-
neous, low in abundance, and found intracellularly, several
tau radioligands are currently in development [55–57].
Novel methods for imaging vascular cognitive impair-
ment are also emerging, including higher resolution imaging
to resolve small infarcts and white matter lesions; physio-
logic imaging approaches such as cerebral blood flow and
permeability; and diffusion tensor imaging and resting-
state functional MRI to assess structural and functional con-
nectivity [58]. However, spatial resolution limits will
continue to prevent direct measurement of microinfarcts,
whose mean diameter may be as small as 200 microns
[59]. Functional imaging of the dopaminergic system using
123I-FP-CIT SPECT (DaTscan, GE Healthcare, Chicago,
IL, USA) may be used to identify dopaminergic deficiency
in parkinsonian diseases, including LBD [60], but it remains
to be determined how this technology can be used to identify
concomitant LB pathology in AD patients.
Several studies have shown that the CSF biomarkers Ab1–
42, tau, and phosphorylated tau may detect AD neuropa-
thology and be useful in clinical practice for diagnosis and
prognosis even in early disease stages [61–65]. These CSF
biomarkers may also aid in differential diagnosis of AD
versus other dementias and other neurologic diseases [66].
However, very few studies have examined CSF biomarkers
in AD patients with well-defined copathologies, especially
with neuropathologic confirmation. In a study of 142
autopsy-confirmed dementia patients (with 38 patients
with AD with LBD or FTLD copathology), CSF Ab1–42,
tau, and phosphorylated tau had robust sensitivity and spec-
ificity in AD with coincidence of other pathologies but did
not differentiate between pure AD and AD with copatholo-
gies [67]. Likewise, in autopsy-characterized subjects from
Alzheimer’s Disease Neuroimaging Initiative, CSF Ab1–42,
tau, and phosphorylated tau did not differ between pureAD and AD with coincident TDP-43 or LB pathology
[63]. Novel CSF biomarkers are needed for in vivo identifi-
cation of copathologies in AD patients. One candidate is
CSF neurofilament light protein (NFL), which may indicate
damage of large-diameter myelinated axons and white mat-
ter lesions [68]. Specifically, high CSF NFL levels are seen
in FTD [69], especially in tau-negative FTLD [70], and in
patients with small-vessel disease in the brain, including
AD dementia with vascular copathology [71]. CSF NFL
may also provide prognostic information because it corre-
lates with higher mortality in patients with and without
AD [71]. Another candidate biomarker is CSF a-synuclein,
which is reduced in the presence of LB pathology [72,73].
Several studies have found reduced levels of CSF
a-synuclein in synucleinopathies (including LBD, PD, and
multiple system atrophy) compared with AD [73–76].
Hypothetically, this could inform on LB copathology in
AD because LBD-like symptoms are correlated with lower
CSF a-synuclein levels in AD dementia patients [77]. How-
ever, two neuropathologic studies did not find any difference
in CSF a -synuclein levels between AD patients with and
without LB copathology [63,75]. The use of CSF
a-synuclein is complicated by several confounding factors,
including increased CSF a-synuclein as response to
neuronal injury [78,79] and susceptibility to analytical
factors, especially blood contamination of CSF [80]. Other
a-synuclein–related biomarkers, including a-synuclein olig-
omers, may bemore specific to the presence of LB pathology
[81]. Recently, CSF biomarkers of synaptic function have
been developed and tested in AD [82,83], but studies on
differential diagnosis and copathologies are lacking.
Likewise, CSF markers of inflammation [84] and microglial
function [85–87] are altered in AD and may be explored
further for differential diagnosis and tested in autopsy-
confirmed subjects.3.5. Implications of multiple/variable pathologies on
clinical trials
Multiple pathologic processes have substantial implica-
tions on the design of clinical trials. Because the various
pathologic processes have additive effects on cognition,
when enrolling a heterogeneous population, greater numbers
of subjects will be needed to achieve the power necessary to
see an effect from an agent targeting just one pathology (e.g.,
amyloid) that is related to decline. Study cohorts in which
diagnostic heterogeneity is not well defined could also
lead to erroneous conclusions because decline may be
different among the various subgroups. Although randomi-
zation should equally allocate both measured and unmea-
sured accompanying pathologies between treatment arms
and thus prevent confounding, the potential for off-target
drug effects on accompanying pathologic processes could
lead to erroneous conclusions. The alternative—screening
out individuals with non-AD pathologies including cerebro-
vascular disease—comes with its own set of problems,
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potential to eliminate decliners, and the resulting lack of
generalizability because so many people with these other
pathologic findings also have AD. Another alternative may
be clinical trials focused on people with sporadic early-
onset AD, that is, onset before 65 years of age, which may
reduce the likelihood of copathologies. The current trend
is to intervene early in the disease process when amyloid
and/or tangles may not have reached some theoretical crit-
ical threshold. However, the slope of decline is less steep,
requiring even more power to see an effect. In fact, treatment
in secondary prevention or primary intervention typically
translates into longer treatment periods and larger patient
numbers to detect the smaller absolute change on outcome
measures.
Postmortem pathology studies have been invaluable in
illuminating underlying disease processes, and there was a
suggestion that signed intent of willingness of participants
to enroll in a brain donation program should be required
for participation in a clinical trial; however, this requirement
could complicate recruitment and retention efforts, and it
would take many years to accrue sufficient postmortem ex-
aminations, particularly in trials enrolling MCI patients. It
is worth noting that this has not been an impediment to
development of neuroimaging markers [88].
In the future, disease-modifying trials will need to be
large, and international trials will be needed, increasing
the variability across centers. Identifying people who are
likely to have progressive disease will thus become even
more important for early disease treatments. Although the
expertise for identifying such subjects has largely been
located in academic medical centers, these centers have
not demonstrated the ability to enroll the large numbers of
subjects needed. Better education of general neurologists
and general practitioners could help rectify this problem
by encouraging them to refer potential subjects for clinical
trials. There are also systems-based barriers that hinder
enrollment in clinical trials because detailed interviews are
needed to evaluate and accurately diagnose patients. On
the other hand, clinicians in current medical practice are
often incentivized to see more patients in less time.
Although investigators debate the pros and cons of testing
drugs in homogenous versus heterogeneous populations,
they agree on the need for better imaging and fluid bio-
markers for vascular disease, tau, a-synuclein, and
TDP-43. In addition, even if the trial targets one pathologic
process, measuring markers of other pathologies will
undoubtedly lead to improved understanding of the results
of interventions and prepare the field for future treatments
that target multiple pathologies simultaneously.4. Conclusions
The criteria used to classify neurodegenerative diseases
are based on the assumption of unitary clinicopathologic
syndromes—namely that the underlying neuropathologycan be accurately predicted based on the clinical phenotype
and that, as Occam’s razor would postulate, a dementia syn-
drome in an individual patient is due to a single neuropath-
ologic process. However, postmortem studies have revealed
the real picture to be much more complex. The relationship
between clinical syndrome and underlying neuropathology
is probabilistic rather than deterministic: the same pheno-
type can be caused by different pathologies, and the same
pathology can produce different phenotypes. Furthermore,
a dementia syndrome is uncommonly related to a single pro-
cess: Multiple pathologies seem to be the rule rather than the
exception, especially in older individuals.
Multiple pathologic findings also complicate clinical tri-
als. Although extremely common, they are mostly undetect-
able with current clinical, imaging, or fluid biomarker tools.
New tools are needed to evaluate proteins other than amyloid
and tau and to distinguish clinically relevant from “silent”
cerebrovascular disease. If these tools were available and
used to exclude subjects with multiple pathologic findings,
the remaining cohort would likely not be representative of
larger population of elderly individuals with dementia.
Roundtable participants debated the question of whether
clinical phenotyping has limited promise in therapy develop-
ment. They concluded that clinical phenotyping remains
important and may itself be considered a biomarker, but
biochemical and imaging biomarkers that can detect multi-
ple pathologies are also needed to enable the development
of better treatments. The challenge to the field is to define
different etiologies according to the most definitive available
biomarkers and then to assess how those biomarkers are
affected by disease-modifying therapies.
In terms of therapy development, the high prevalence of
multiple pathologic findings among individuals with clinical
diagnosis of AD suggests that treatments for each pathologic
entity may need to be developed, as well as treatments that
target upstream or downstream events such as inflammation,
network dysfunction, neurochemical changes, synaptic loss,
and neuronal death. These treatments may then need to be
used in combination to effectively treat and eventually
cure AD and other dementing illnesses.Acknowledgments
None of the coauthors report any funding conflicts related to
this paper. Eric Smith reports grant funding from the Cana-
dian Institutes of Health Research, Canadian Partnership
Against Cancer, and Alberta Innovates–Health Solutions.
Maria C. Carrillo and James A. Hendrix are full-time
employees of the Alzheimer’s Association. Mark Forman
is a full-time employee of Merck. Susan DeSanti is a full-
time employee of Piramal Pharma, Inc. David S. Miller is
a full-time employee of Bracket Global. Nicholas Kozauer
was a full-time employee of Quintiles in October 2014 at
the time of the Research Roundtable meeting. Christopher
Randolph is an employee of MedAvante and Loyola Univer-
sity Medical Center. John R. Sims is a full-time employee of
G.D. Rabinovici et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 83-91 89Eli Lilly & Co. Maria Isaac is a full-time employee of the
European Medicines Agency. Lisa J. Bain is an independent
science writer under contract from the Alzheimer’s Associ-
ation for writing this publication.
The authors thank Meredith McNeil for logistical planning
of the roundtable as well as the contributing speakers:
Adriano Aguzzi, MD, PhD, Dennis Dickson, MD, Matthew
Frosch, MD, PhD, Steve Greenberg, MD, PhD, William Jag-
ust, MD, Keith Josephs, MD, Brad Miller, MD, PhD, Leo-
nard Petrucelli, PhD, Julie Schneider, MD, Andrew
Siderowf, MD, Harry Vinters, MD, and Wagner Zago, PhD.RESEARCH IN CONTEXT
1. Systematic review: This review summarizes the pre-
sentations made at the October 2014 Research
Roundtable meeting. Each presenter reviewed the
literature of recent work of their specific topic area
within the overall area of how overlapping pathol-
ogies affect the diagnosis and treatment of clinical
Alzheimer’s disease (AD) and other dementia pheno-
types.
2. Interpretation: This article posits that dementia syn-
drome is most commonly related to multiple pathol-
ogies especially in older individuals, rather than a
single process.
3. Future directions: A better understanding of the
complexity of clinical phenotypes is needed.
Biochemical and imaging biomarkers that can detect
multiple pathologies may help enable the develop-
ment of better treatments.
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